Key result
Cardiac biomarkers, particularly high-sensitivity troponin assays used alongside clinical assessment and ECG, can improve early diagnosis, risk stratification, and safe discharge of patients with chest pain.
Answers are grounded in this paper and cite their sources.
Novel cardiac biomarkers and multimarker panels show promise in improving the rapid triage and risk stratification of patients presenting with acute chest pain.
When patients present with chest pain, their levels of cardiac biomarkers are only one piece of the clinical picture, albeit an important one. Together with the history, physical examination, and electrocardiography (ECG), these levels help estimate the probability that the patient is experiencing an acute coronary syndrome and will have an adverse clinical outcome.
No takes yet. Share an insight, caveat, or question.
Mosleh et al. (2013) conducted a review in Chest pain and suspected acute coronary syndrome. Cardiac biomarkers (e.g., high-sensitivity troponin, BNP, cystatin C) was evaluated. Cardiac biomarkers, particularly high-sensitivity troponin assays used alongside clinical assessment and ECG, can improve early diagnosis, risk stratification, and safe discharge of patients with chest pain.
Synapse has enriched 10 related papers. Consider them for comparative context: